Clinical Plenary #1
Nov
2026
Description
Very recent experiences of gene therapy for non-liver disorders has, in rare cases, led to several serious hepatic toxicities including liver failure. Understanding hepatic pathophysiology, monitoring and therapeutic approaches in the modern era of gene therapy is crucial.
Presentations
8:30 AM
- 8:45 AM
Convention Center - General Session, Hall A
CRISPR-Cas12 Based Gene Editing Therapy for Primary Hyperoxaluria Type 1: a phase 1 clinical trial
Taihua Yang, PhD | Abstract Presenter
8:45 AM
- 9:00 AM
Convention Center - General Session, Hall A
BULEVIRTIDE MONOTHERAPY PREVENTS LIVER DECOMPENSATION IN HDV-RELATED CIRRHOSIS: 3-YEAR RESULTS FROM A EUROPEAN, RETROSPECTIVE, CONTROLLED COHORT STUDY
Elisabetta Degasperi | Abstract Presenter
9:00 AM
- 9:15 AM
Convention Center - General Session, Hall A
Decoupling of Disease Activity and Fibrosis in MASH: Insights from Contemporary Biopsy Cohorts in the GLP-1 Receptor Agonist Era
Winston Dunn, MD, , FAASLD | Abstract Presenter
9:15 AM
- 9:30 AM
Convention Center - General Session, Hall A
GLP1R Gene Variants Modify Longitudinal Outcomes and GLP1 Receptor Agonist Response in MASLD: A Whole-Genome Sequencing Pharmacogenomic Study
Sarpong Boateng, MD, MPH | Abstract Presenter
